RxDoctor Payments Data

Joel Rivera-Rodriguez, MD

Internal Medicine · Clearwater, FLNPI 1497062186

Payments from drug & device makers

$2,548in general payments, 2019–2025

Across 129 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$635
  • AstraZeneca$366
  • Novo Nordisk$284
  • Genentech USA, Inc.$209
  • Pfizer$182
  • Exact Sciences$159
  • plus $713 from 11 others

What the payments were for

  • Food & beverage$2,544100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,548 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$5,770
Medicare patients
23
Services billed
94

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide124$130,018
OzempicSemaglutide104$111,424
EliquisApixaban103$100,362
MounjaroTirzepatide64$70,694
XareltoRivaroxaban45$53,313
JardianceEmpagliflozin45$51,846
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$40,615
FarxigaDapagliflozin Propanediol36$38,444
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$27,673
LinzessLinaclotide30$23,548
EntrestoSacubitril/Valsartan23$18,871
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$16,944
Stiolto RespimatTiotropium Br/Olodaterol Hcl35$16,313
Tresiba Flextouch U-100Insulin Degludec37$16,053
Celecoxib170$12,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$115$200,712188 claims
Novo NordiskOzempic, Novolog$284$113,720125 claims
PfizerEliquis$182$100,362103 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta$366$84,045131 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$153$73,88391 claims
Johnson & JohnsonXarelto$120$53,31345 claims
GSKTrelegy Ellipta, Anoro Ellipta$635$52,71083 claims
AbbVieLinzess, Synthroid$40$25,62847 claims
NovartisEntresto$28$18,87123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →